Gut microbiota, hypertension and chronic kidney disease: Recent advances.
Blood pressure
Ckd
GLP-1
Inflammation
Probiotics
TLR-4
Journal
Pharmacological research
ISSN: 1096-1186
Titre abrégé: Pharmacol Res
Pays: Netherlands
ID NLM: 8907422
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
25
09
2017
revised:
29
12
2017
accepted:
22
01
2018
pubmed:
30
1
2018
medline:
24
3
2020
entrez:
30
1
2018
Statut:
ppublish
Résumé
A large number of different microbial species populates intestine. Extensive research has studied the entire microbial population and their genes (microbiome) by using metagenomics, metatranscriptomics and metabolomic analysis. Studies suggest that the imbalances of the microbial community causes alterations in the intestinal homeostasis, leading to repercussions on other systems: metabolic, nervous, cardiovascular, immune. These studies have also shown that alterations in the structure and function of the gut microbiota play a key role in the pathogenesis and complications of Hypertension (HTN) and Chronic Kidney Disease (CKD). Increased blood pressure (BP) and CKD are two leading risk factors for cardiovascular disease and their treatment represents a challenge for the clinicians. In this Review, we discuss mechanisms whereby gut microbiota (GM) and its metabolites act on downstream cellular targets to contribute to the pathogenesis of HTN and CKD, and potential therapeutic implications.
Identifiants
pubmed: 29378252
pii: S1043-6618(17)31208-2
doi: 10.1016/j.phrs.2018.01.013
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
390-408Informations de copyright
Copyright © 2018. Published by Elsevier Ltd.